Market Leader Strategies: AstraZeneca Defending its Turf
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : BSTR271
Case Length : 19 pages
Period : 2001-2007
Pub Date : 2008
Teaching Note : Available
Organization : AstraZeneca
Plc.
Themes : Growth Strategies | Product Lifecycle Management
Industry : Pharma and Biotech
Countries : Europe; USA
To download Market Leader Strategies: AstraZeneca Defending its Turf case study
(Case Code: BSTR271) click on the button below, and select the case from the list of available cases:
OR
Buy With PayPal
|
Price:
For delivery in electronic format: Rs. 400;
For delivery through courier (within India): Rs. 400 + Shipping & Handling Charges extra
» Business Strategy Case Studies
» Case Studies Collection
» Business Strategy Short Case Studies
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Case Studies by Area
» Case Studies by Industry
» Case Studies by Company
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
|
<< Previous
Excerpts
Background Note
On April 6, 1999, two pharmaceutical companies - Astra AB (Astra) of Sweden and UK-based Zeneca Group Plc (Zeneca)
- merged and formed a single entity called AstraZeneca. Analysts felt that the amalgamation would be smooth as the two companies shared parallel work cultures and visions pertaining to the pharmaceutical industry. (Refer to Exhibit I for AstraZeneca's logo)...
Losec/Prilosec - The Purple Pill
Post merger, Losec/Prilosec was one of AstraZeneca's most successful brands.
It
was the most successful PPI in the market and was responsible for the company
being considered the market leader in the treatment of gastric acid related
diseases.
In 1999, the market for the treatment of gastric acid related diseases
was US$ 18 billion and Losec/Prilosec had sales of US$5.9 billion...
|
|
The Impending Shark Fin
Losec/Prilosec was a cash cow for AstraZeneca. The brand's
sales between 1997 and 2001 were a whopping US$26 million. With the patent of
the brand set to expire in 2001, the company was in danger of losing its market
leadership in the PPI market as well as in the treatment for acid-related
disease market. PPIs were a fast growing segment with Losec/Prilosec
spearheading the sales...
|
|
The Shark Fin Project
But the erstwhile Astra had already planned for this eventuality. In the
year 1995, Astra along with Merck, formed a team of experts which
included marketers, lawyers, and scientists, who studied Prilosec and
came out with around 50 possible solutions to outsmart the
patent-expiration peril...
Launching Nexium
The company received marketing approval for the drug in the EU in July
2000 and in the US in February 2001. The drug was first launched in
Sweden. In 2000, the brand was also launched in the UK, Germany,
Ireland, Norway, and Denmark... |
Excerpts Contd...>>
|
